The 18,600 Shares in FibroGen, Inc (FGEN) Acquired by Alambic Investment Management L.P.

The 18,600 Shares in FibroGen, Inc (FGEN) Acquired by Alambic Investment Management L.P.

Alambic Investment Management L.P. acquired a new position in FibroGen, Inc (NASDAQ:FGEN) during the third quarter, Holdings Channel reports. The firm acquired 18,600 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.

Several other institutional investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new position in FibroGen during the second quarter worth $106,000. Acrospire Investment Management LLC raised its position in FibroGen by 240.2% in the second quarter. Acrospire Investment Management LLC now owns 6,657 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 4,700 shares during the period. Teacher Retirement System of Texas raised its position in FibroGen by 15.7% in the second quarter. Teacher Retirement System of Texas now owns 6,891 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 937 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in FibroGen during the second quarter worth $180,000. Finally, Blair William & Co. IL raised its position in FibroGen by 17.7% in the second quarter. Blair William & Co. IL now owns 11,590 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,740 shares during the period. 48.21% of the stock is owned by hedge funds and other institutional investors.

FibroGen, Inc (NASDAQ:FGEN) traded up 5.50% during midday trading on Wednesday, hitting $24.95. The stock had a trading volume of 782,638 shares. The company’s market cap is $1.58 billion. The firm has a 50-day moving average of $21.98 and a 200-day moving average of $19.77. FibroGen, Inc has a 12-month low of $14.38 and a 12-month high of $25.65.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.21. FibroGen had a negative return on equity of 40.38% and a negative net margin of 45.93%. The firm had revenue of $30.10 million for the quarter, compared to analysts’ expectations of $24.30 million. Equities research analysts forecast that FibroGen, Inc will post ($0.99) EPS for the current year.

A number of equities analysts recently commented on FGEN shares. Zacks Investment Research raised FibroGen from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Friday, November 11th. Leerink Swann reissued a “buy” rating and set a $52.00 price target on shares of FibroGen in a research note on Wednesday, November 9th. Finally, Stifel Nicolaus reissued a “positive” rating on shares of FibroGen in a research note on Wednesday.

In other FibroGen news, VP Pat Cotroneo sold 2,344 shares of the company’s stock in a transaction on Monday, December 12th. The stock was sold at an average price of $22.05, for a total transaction of $51,685.20. Following the transaction, the vice president now directly owns 132,248 shares in the company, valued at $2,916,068.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas B. Neff sold 37,798 shares of the company’s stock in a transaction on Thursday, January 12th. The stock was sold at an average price of $23.85, for a total value of $901,482.30. Following the transaction, the chief executive officer now owns 3,298,100 shares in the company, valued at $78,659,685. The disclosure for this sale can be found here. 14.90% of the stock is owned by corporate insiders.

About FibroGen

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).

Related posts

Leave a Comment